Recently, the Idarubicin Hydrochloride Injection submitted by Kindos Pharmaceutical Co., LTD., a subsidiary of King-Friend Co., LTD., has received a defection-free approval in the first round of review by the US Food and Drug Administration (FDA). The commercial finished product will be available for sale in the US market in the near future.

Idarbicin Hydrochloride Injection, when used in combination with other anti-leukemia drugs, is suitable for the treatment of adult acute myeloid leukemia (AML) and is a market shortage product that the FDA focuses on. Kindos will become the first Chinese pharmaceutical enterprise to export this variety to the US market.

Since the Spring Festival this year, Kindos has maintained a good operational trend of having new varieties approved for marketing in the United States every month. It has always been a growth pole for the internationalization of China's biopharmaceuticals and has continuously injected stability into the high-quality development of Sichuan's foreign trade.

Kindos will continue to drive high-quality products and services to a new level, assist more partners in exploring new international markets and building strategic backups for the global supply chain, and jointly contribute the collaborative strength of the industrial chain to the higher-quality development of the domestic and international dual circulation of the biopharmaceutical industry.